EZH2 and colonic neoplasm: Researchers discovered that co-exposure to low-dose DNMT inhibitors (DNMTi) and inhibitors of the Enhancer of Zeste Homolog 2 (EZH2, a catalytic subunit of the histone methyltransferase Polycomb repressive complex 2 (PRC2)) sensitizes colon cancer cells [251].